- Novavax's (NVAX) RSV vaccine is "under-appreciated," FBR says, adding that the company's pandemic vaccine program is "even less well appreciated."
- The new note largely echoes similar research out last month, but analyst William Tanner's language regarding the company's pandemic program looks a bit more upbeat. "Investors should ignore the program no more," Tanner says, adding that "contrary to the belief that [recent AH7N9] data had already been released, they were, in fact, a new disclosure."
- NVAX is rated Outperform.
- Price target remains $11.
FBR still bullish on Novavax after publication of data from vaccine study
Nov 18 2013, 07:57 ET